Cosmetic/pharmaceutical compositions comprising .beta.-adrenergic agonists/substance P antagonists
AssigneeSociete L'Oreal S.A.
InventorsLionel Breton, Olivier de Lacharriere, Jacques Leclaire
Life of this patent
Estimating the term…
Abstract
Cosmetic/pharmaceutical compositions, well suited for the treatment of a variety of mammalian disorders of, for example, the skin, hair and/or mucous membranes, a manifestation of which is an excess in the synthesis and/or in the release of substance P, e.g., for the treatment of cutaneous disorders and sensitive skin, comprise an effective substance P antagonist amount of at least one .beta.-adrenergic agonist, e.g., salbutamol, in a cosmetically/pharmaceutically acceptable medium therefor.
Claims4
A method for the treatment of a mammalian cutaneous disorder, a manifestation of which is at least one of the following:
- excess in the synthesis of substance P, and an excess in the release of substance P, comprising administering at least one .beta.-adrenergic antagonist selected from the group consisting of salbutamol, 4-3-(1,1-dimethylethyl)amino!-2-hydroxypropyl!-1,3-dihydro-2H-benzimidaz ol-2-one hydrochloride!, nylidrin, salmeterol, fenoterol, terbutaline, pirbuterol, and combinations thereof, wherein said disorder is selected from the group consisting of pruriginous diseases, urticaria, atopic dermatitides, contact dermatitides, pruriginous dermatoses, and erythemal dermatoses, comprising administering a therapeutically effective amount of at least one .beta.-adrenergic antagonist.
Dependencies are inferred from the claim text.